- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06012981
Psychological Treatment in Psychiatric Inpatient Care
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mårten J Tyrberg, PhD
- Phone Number: +4621174373
- Email: marten.tyrberg@regionvastmanland.se
Study Locations
-
-
Västmanland
-
Västerås, Västmanland, Sweden, 72189
- Hospital of Västmanland, Västerås
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years old or older.
- Treated according to the compulsory psychiatric care act.
- Meet the criterion of informed consent.
Exclusion Criteria:
- Lack the cognitive ability to acquire the treatment intervention, such as impaired attention, memory, logic and reasoning, and also auditory and visual processing. This will be based on a clinical assessment by the ward team, including the attending psychiatrist and a clinical psychologist.
- Ongoing psychological treatment parallel to the admission.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Acceptance & Commitment Therapy (ACT)
Psyhotherapy based on principles of functional analysis, behavioral activation, and experiential avoidance.
|
The treatment is based on a variant of CBT, as briefly referred to before, ACT. In short, the treatment consists of identifying central and important areas of life, and how to approach these even though you are also struggling with persistent and challenging problems. In this study, the treatment intervention is flexibly constructed, focusing on several central principles based on ACT. These can be applied during one or numerous sessions. The intervention is a flexible application of clinical functional analysis, as well as a couple of selected interventions which, in terms of experience and in previous studies, have been shown to work well for the current group (24-hour psychiatric patients with complex problems) and which are individually adaptable to the nature of the problem and degree. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Personal Questionnaire
Time Frame: Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
|
Scores range from 1-4 per item (number of items might differ between patients as the measure is individually constructed.
Higher scores correspond to worse outcome.
|
Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
|
Change in Bull's Eye Values Survey
Time Frame: Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
|
The score ranges from 0-28, higher scores corresponding to better outcome.
|
Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
|
Change in PHQ-9
Time Frame: Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
|
The score ranges from 0-27, higher scores corresponding to worse outcome.
|
Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
|
Change in GAD-7
Time Frame: Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
|
The score ranges from 0-21, higher scores corresponding to worse outcome.
|
Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
|
Change in Psy-flex
Time Frame: Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
|
The score ranges from 6-30, higher scores corresponding to better outcome.
|
Four times daily, from point of inclusion to after a minimum of five data points (approximately a day and a half) after last treatment session
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kent Nilsson, Professor, Uppsala University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 280468
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychosis
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)RecruitingFirst Episode Psychosis (FEP) | Clinical High Risk for Psychosis (CHR)United States
-
University of UdineNational Research Council (CNR), Institute of Biomolecular Chemistry (ICB)...RecruitingClinical High Risk for Psychosis | Ultra High Risk for Psychosis | Attenuated Psychotic SymptomsItaly
-
University of New MexicoNational Institute of Mental Health (NIMH)CompletedPsychosis | Clinical High Risk for Psychosis | First Episode PsychosisUnited States
-
Chulalongkorn UniversityNational Research Council of Thailand; Thanyarak InstituteCompletedMethamphetamine-induced PsychosisThailand
-
Shanghai Jiao Tong University School of MedicineGuangzhou Psychiatric Hospital; Suzhou Psychiatric Hospital; Tianjin Anding Hospital and other collaboratorsRecruitingSchizophrenia; Psychosis | Clinical High Risk | First Episode PsychosisChina
-
University of California, San DiegoCenter for Medicinal Cannabis ResearchRecruitingEarly PsychosisUnited States
-
Yale UniversityCompleted
-
University of TorontoUniversity of British Columbia; Centre for Addiction and Mental Health; Queen... and other collaboratorsNot yet recruitingPsychotic Disorders | Schizophrenia | Psychosis | Schizophrenia; Psychosis
-
Northwell HealthNational Institute of Mental Health (NIMH)RecruitingFirst Episode PsychosisUnited States
-
State reference center for psychosocial careUniversity of ValenciaCompleted
Clinical Trials on ACT
-
Idorsia Pharmaceuticals Ltd.CompletedHealthy SubjectsNetherlands
-
Idorsia Pharmaceuticals Ltd.Completed
-
Azusa Pacific UniversityWithdrawnAnxiety Disorders | Stress Disorders, Traumatic | AnxietyUnited States
-
Karolinska InstitutetRegion Stockholm; Forte; Stiftelsen Frimurarna BarnhusetActive, not recruitingDepression | Stress, Psychological | Intellectual Disability | Anxiety | Neurodevelopmental Disorders | Traumatic Brain Injury | Autism Spectrum Disorder | Parents | Attention Deficit Hyperactivity Disorder | Physical DisabilitySweden
-
University of CoimbraFundação para a Ciência e a TecnologiaUnknown
-
University College DublinCompletedInflammatory Bowel DiseaseIreland
-
Idorsia Pharmaceuticals Ltd.Terminated
-
Georgia State UniversityRecruiting
-
Idorsia Pharmaceuticals Ltd.CompletedStable Coronary Artery DiseaseDenmark, Netherlands, Singapore, Canada, United Kingdom, United States, Germany, Sweden